Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients

Abstract

A previous study (LMB89) of the French Society of Pediatric Oncology for childhood mature B-cell lymphoma (B-NHL) demonstrated a 92% 3-year event-free survival (EFS) for intermediate-risk group B defined as "non-resected" stage II/I and CNS-negative advanced-stage IIV/IV (70% of cases). We performed the FAB/LMB96 trial to assess the possibility of reducing treatment in children/adolescents with intermediate-risk B-NHL without jeopardizing survival. "Early responding" patients (tumor response > 20% at day 7) were randomized in a factorial design between 4 arms, 2 receiving half-dose of cyclophosphamide in the second induction course with cyclophosphamide, Oncovin (vincristine), prednisone, Adriamycin (doxorubicin), methotrexate (COPADM) and 2 not receiving the maintenance course M1. A total of 657 patients were randomized (May 1996 to June 2001) and 637 were analyzed. The analysis showed no significant effect of any of the treatment reductions on EFS and survival. The 4-year EFS was 93.4% and 90.9% in the groups with full-dose and half-dose of cyclophosphamide (RR = 1.3, P = .40) and 91.9% and 92.5% in the groups with and without M1 (RR = 1.01, P = .98). There was no interaction between the 2 treatment reductions or between each treatment reduction and LDH level or histologic subtypes (Burkitt/Burkitt-like or large B-cell). Children/adolescents with intermediate-risk B-NHL who have an early response and achieve a complete remission after the first consolidation course can be cured with a 4-course treatment with a total dose of only 3.3 g/m2 cyclophosphamide and 120 mg/m2 doxorubicin.

Figures

Figure 1

Treatment schema and events according to the treatment arm. COP: cyclophosphamide (300 mg/m2, day 1), Oncovin (vincristine; 1 mg/m, day 1), prednisone (60 mg/m2/d, days 1-7), plus intrathecal methotrexate (IT MTX, day 1); COPADM: cyclophosphamide (1.5 g/m2 in COPADM1, 3 g/m2 in COPADM2), Oncovin (2 mg/m2, day 1), prednisone (60 mg/m2/d, days 1-7), Adriamycin (doxorubicin; 60 mg/m2, day 2), high-dose (HD) MTX (3 g/m2 in 3-h infusion, day 1, plus leucovorin rescue starting at hour 24 until serum MTX level is less than 1 × 10−7 M) plus IT MTX, day 2 and day 6. CYM: cytarabine (100 mg/m2 in continuous infusion, days 2-6, plus IT cytarabine, day 6), HD MTX (3 g/m2 in 3-h infusion, day 1, plus leucovorin rescue, plus IT MTX, day 2). M1: cyclophosphamide (1 g/m2), Oncovin (2 mg/m2, day 1), prednisone (60 mg/m2/d, days 1-7), Adriamycin (60 mg/m2, day 2), HD MTX (3 g/m2 in 3-h infusion, day 1, plus leucovorin rescue starting at hour 24) plus IT MTX, day2. IT: intrathecal injections: all are with hydrocortisone and age-adjusted. Oncovin: max 2 mg.

Figure 2

Flow chart of the trial.

Figure 3

Kaplan-Meier curves for survival, EFS, and FFS. Vertical bars denote 95% CI of the actuarial rates. (A) Kaplan-Meier estimates of EFS of all patients and of randomized patients. Solid black line indicates all patients, 4-year rate, 90.2%; dotted line, randomized patients, 4-year rate from start of treatment, 92.4% (92.2% from time of randomization). (B) Kaplan-Meier estimates of EFS according to cyclophosphamide dose randomization in the second COPADM course. Black line indicates full-dose CPM in second COPADM, 4-year rate, 93.4%; gray line, half-dose CPM in second COPADM, 4-year rate, 90.9% (C) Kaplan-Meier estimates of EFS according to maintenance course M1 randomization. Black line indicates with M1, 4-year rate, 91.9%; gray line, without M1, 4-year rate, 92.5%. (D) Kaplan-Meier estimates of EFS according to the 4 arms of randomization. COPADM1-2, M1 (standard), 4-year rate, 92.5%; COPADM1-2, no M1, 4-year rate, 94.4%; 2 COPADM1, M1, 4-year rate, 91.3%; 2 COPADM1, no M1, 4-year rate, 90.5.